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1  Introduction
liver toxicity is still a major problem for clinicians, pharma-
ceutical companies, and regulators (Andrade et al., 2005; lar-
rey, 2002; lasser et al., 2002; lee, 2003; Reuben et al., 2010). 
Intensive research is done worldwide to develop predictive in 
vitro screening systems with sufficient sensitivity and specifi-
city. Reliable predictive in vitro tools would not only improve 
human public health by reducing exposure to unsafe drugs but 
also enhance animal welfare by replacing, refining, and reduc-
ing animal tests, thus providing an alternative to in vivo animal 
testing in human health risk assessment. Mode-of-action (MoA) 
is defined as “a description of key events or processes by which 
an agent causes a disease state or other adverse effect” (NRC, 
2007, p. 38). Key events are measurable events that are critical 
to the induction of the toxicological response as hypothesized 
in the postulated MoA (Boobis et al., 2008; Sonich-Mullin et 
al., 2001; WHO Harmonization Project Document, 2007). Key 
events along this toxicological pathway also could be used to 
characterize the toxic potential of a chemical instead of using 
patho-physiologic categories such as apoptosis or necrosis, as 
well as to facilitate the assessment of other chemicals that share 
the same MoA. 
At this point, the MoA for hepatotoxicity is not yet really de-
fined. Some events, such as mitochondrial damage (Xu et al., 
2008; Kaplowitz, 2002) and oxidative stress, seem to play a key 
role in various mechanisms of chemical-induced liver toxicity 
(Jaeschke et al., 2002). In this work, we focus our attention par-
ticularly on oxidative stress that is reported to be involved in 
toxic cell injury (edwards and Preston, 2008; Guengerich and 
MacDonald, 2007; Kaplowitz, 2004; liebler and Guengerich, 
2005; Russmann et al., 2009, Simmons et al., 2009). We tested 
the crucial role of oxidative stress in hepatotoxicity, exposing 
HepaRG cells to 92 chemicals with known hepatotoxic effects. 
HepaRG is a metabolically competent hepatic cell model (An-
thérieu et al., 2010), derived from a liver tumor of a female 
suffering from hepatocellular carcinoma (Gripon et al., 2002). 
These cells, seeded at high confluence in the presence of 2% 
DMSO, insulin, and hydrocortisone differentiate into hepato-
cyte-like cells resembling primary hepatocytes and biliary epi-
thelial cells (Cerec et al., 2007). Differentiated HepaRG cells 
express phase II enzymes, nuclear receptors, transporters (le 
Vee et al., 2006), liver-specific protein (Guillouzo et al., 2007) 
and various CYPs (Aninat et al., 2006; turpeinen et al., 2009; 
Anthérieu et al., 2010). Oxidative stress was tested in these cells 
by measuring the formation of reactive oxygen species (ROS). 
In the same cell, a multiparametric analysis allowed the collec-
tion of information on cell loss, nuclear area, and nuclear inten-
sity. the test chemicals were grouped consecutively according 
to their effect on ROS formation, viability, and DNA conden-
sation. the results from this cell-based assay could ultimately 
be used to prioritize chemicals according to their potential liver 
toxicity. 
2  Materials and methods
Chemicals and supplies
HepaRG cells were obtained from Biopredic International 
(Rennes, France) and stored in liquid nitrogen. William’s e me-
dium, l-glutamine, penicillin/streptomycin, and trypsin-eDtA 
were acquired from Invitrogen. Insulin and hydrocortisone 
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were purchased from Sigma-Aldrich. HyClone Fetalclone III 
serum, Hoechst and DHE dyes were from Thermo Scientific. 
the 96-well clear bottom black polystyrene microplates were 
from Corning. test drugs and chemicals were purchased from 
Sigma-Aldrich. Stock solutions were prepared in DMSO for all 
test compounds. 
Cell culture and differentiation
Human hepatocellular carcinoma cells HepaRG were cul-
tured in William’s E medium supplemented with 10% serum, 
1% L-glutamine, 1% penicillin/streptomycin, 5 μg/ml bovine 
insulin and 50 µM hydrocortisone hemisuccinate. the cells 
were seeded at a density of 4x106 cells in 150 cm2 flasks and 
the medium was refreshed every two days. After two weeks, 
2% DMSO was added to the culture medium to stimulate dif-
ferentiation. Differentiation medium was changed every 2 days 
for two weeks. Finally, the differentiated cells were gently har-
vested with trypsin-eDtA and seeded into 96-well clear bottom 
black plates at a density of 50,000 cells/well using the StARlet 
Hamilton platform.
Treatment with test compounds
All chemicals were initially solubilized in 100% DMSO. They 
were then diluted in culture medium (described above) but with 
5% serum. Quantitative high-throughput screening (qHTS) 
(Inglese et al., 2006) format was used. to assess hepatotoxic-
ity, the HepaRG cells were exposed to 92 chemicals at 16 con-
centrations (see Tab. 1) and incubated at 37°C, 5% CO2, 100% 
humidity for 72 h. In each plate, 4 negative control wells (cells 
treated with only DMSO) were included. the experiment con-
sists of three independent biological repeats in which different 
cell batches were used on different days. All the treatment pro-
cedures were completely automated and the entire process was 
managed by Hamilton software.
Staining and endpoint measurements
Chemically treated HepaRG cells were stained for 30 min us-
ing an oxidative stress staining kit (Thermo Scientific) con-
taining dihydroethidium (DHe) and Hoechst 33342 dye. After 
30 min in the incubator at 37°C, 5% CO2, 100% humidity, the 
cells were fixed with 4% formaldehyde (Sigma) for 20 min at 
room temperature. Finally cells were washed twice with PBS 
(Invitrogen) and imaged via a high-content analysis approach 
(HCA) using Cellomics ArrayScan vti. A 10x objective was 
used to collect 10 image fields per well for two fluorescence 
channels with the XF93 filter set. Cell count, nuclear area, 
nuclear intensity, and ROS formation (DHe intensity) param-
eters were collected using the target Activation Bioapplication 
v.4 from Cellomics Scan Software. 
Data analysis
Statistical analysis was performed using Matlab 7.5. software 
for Windows. the raw response data, obtained after cellular ex-
posure to the different compound concentrations, were adjusted 
as follows. First, the mean and standard deviation (SD) were 
calculated for the negative control samples. the normalization 
of the data was performed by subtracting the calculated mean 
from each data point and dividing by the SD. the adjusted re-
sults were plotted against concentration as an average over three 
biological replicates. Upper and lower boundaries (three times 
the SD) were set to define the point of departure (POD). The 
POD is identified as: A) the first concentration at which a per-
manent exit from the defined boundaries occurs or B) the low-
est concentration for which temporary exit occurs. PODs were 
identified for each endpoint being analyzed (cell count, nuclear 
area, nuclear intensity, ROS formation) as displayed in Figures 
4 and 5. A heat map was generated using MeV v4.7 (Multiex-
periment Viewer), software available online.
3  Results
MoA-drug induced hepatotoxicity hypothesis
looking at the various described pathways that lead to differ-
ent features of toxic liver damage, three events are observed 
in all pathogenic processes, which therefore can be called key 
events: metabolic activation, oxidative stress, and mitochon-
drial damage (xu et al., 2008; Jaeschke et al., 2002; Russmann 
et al., 2009; Kaplowitz, 2002; Malhi and Gores, 2008). Once a 
chemical arrives at the liver it is metabolized there. the meta-
bolic alteration may inactivate the chemical or it may result in 
the production of an active metabolite. Subsequently, the toxic 
effects are caused, likewise, by either the parent drug or the re-
active metabolite (Park et al., 2005). Using a mode-of-action 
targeted analysis of the existing literature, we made a hypothesis 
of MoA for hepatotoxicity (Fig. 1). A parent chemical/metabo-
lite can cause:
a) Oxidative stress. Chemical metabolism can produce reactive 
oxygen species, reactive lipid peroxidation, and GSH deple-
tion. this chain reaction can trigger mitochondrial damage 
(Jaeschke and Ramachandran, 2011). 
b) Mitochondrial dysfunction. Metabolites can directly bind 
to mitochondrial proteins, causing direct toxicity via inhi-
bition of the respiratory chain. Damaged mitochondria and 
β-oxidation increase ROS formation leading to oxidative 
stress (Russmann et al., 2009).
c) Protein adduct formation. Protein covalent adducts formed 
after exposure to xenobiotic, activate t cells and induce the 
release of cytokines, causing immune responses (Yang et al., 
2006; Zhang et al., 2011). Consecutive inflammatory proc-
esses then contribute to oxidative stress and mitochondrial 
damage (Adams et al., 2010).
d) Activation of non-parenchymal liver cells. Non-parenchymal 
liver cells exposed to chemicals produce ROS, induce oxida-
tive stress, and induce mitochondrial damage via inflamma-
tion, cytokine release, and fibrosis (pathway not shown in 
Fig. 1) (Poli, 2000).
e) Inhibition of bile transporter systems. either metabolites or 
parent chemicals can cause cholestasis through the inhibition 
of bile transport systems and, consequently, induce inflam-
mation, oxidative stress, and mitochondrial damage (Copple 
et al., 2010; Pauli-Magnus and Meier, 2006).
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these processes can cause various types of liver injury, namely 
hepatitis, necrosis, (lemasters et al., 1999), steatosis, cholesta-
sis (Pauli-Magnus and Meier, 2006), and fibrosis/cirrhosis.
Chemical selection
taking into consideration several chemical libraries, includ-
ing toxCast 320, we decided to select some chemicals that are 
known or suspected to be hepatotoxic. In the chemical selec-
tion step we excluded all the volatile chemicals, and we pri-
oritized the substances that were commercially available and 
soluble in DMSO. A total of 92 chemicals were selected, in-
cluding drugs such as troglitazon, tamoxifen, and nilutamide, 
and pesticides (phenotrin, phralletrin, cyfluthrin, etc.) (Tab.1). 
the choice of these chemicals is envisioned to cover differ-
ent toxicity pathways. Four non-hepatotoxic chemicals (propyl 
4-hydroxybenzoate, Dl-thyroxine, potassium chloride, and 
dibutyl phthalate) were included in the list. Rotenone was used 
as positive control for reactive oxygen species formation. As 
negative control, the HepaRG cells were treated with vehicle 
(DMSO). the cell treatment was performed using a concentra-
tion range of 1x10-4 M up to 1.5x10-9 M. If no effects were 
obtained at 1x10-4 M, the dose of many of these chemicals 
was increased 5- to 10-fold. For a few chemicals, the dose was 
reduced 5- to 10-fold because precipitation was observed in 
the medium. 
HepaRG high-content analysis
After treating two-week-old differentiated HepaRG and stain-
ing them with two fluorescent probes (Fig. 2), we were able 
to measure signals that are directly linked to the hypothetical 
key events of hepatotoxicity described in Figure 1. Hoechst 
and DHE fluorescence staining were quantified using high-
content imaging. Automated imaging analysis performed with 
Cellomics ArrayScan vti and Cellomics Scan software was 
used to measure cell viability, nuclear area and intensity, and 
ROS formation. typical morphological and toxic changes are 
shown in Figure 3. Rotenone produced a marked reduction in 
cell number and nuclear area but an increase in ROS fluores-
cence signal and nuclear intensity (DNA condensation). this 
multiparametric analysis allowed the investigation of the pos-
sible mechanism by which a chemical exerts its hepatotoxicity 
and whether this is led by the production of ROS. In Figure 4, 
the dose response curves are reported for a representative set of 
six chemicals, i.e., amiodarone hydrochloride, troglitazone, ro-
Fig. 1: Diagram representing the mode-of-action proposed in which oxidative stress and mitochondrial damage plays a  
key role in the different known mechanisms of hepatotoxicity
Extensive literature research has lead to the proposed hypothesis that oxidative stress plays a crucial role in various hepatotoxicity 
pathways. This key event can therefore be used as a marker for potential chemical induced hepatotoxicity.
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Tab. 1: Selected reference chemicals
The selected chemicals with their corresponding CAS number and concentrations at which each were tested are reported in  
the following table.
Compound  CAS #  Tested in vitro concentration range (M)
Carbamazepine  298-46-4  1.5 x10-9 - 1x 10-4
Kaempferol  520-18-3  1.5 x10-9 - 1x 10-4
1,2-dichlorobenzene  95-50-1  1.5 x10-8 - 1x 10-3
Phthalic anhydride  85-44-9  1.5 x10-8 - 1x 10-3
Triticonazole  131983-72-7  7.6 x10-10 - 5x 10-5
Thiabendazole  148-79-8  7.6 x10-10 - 5x 10-5
Vinclozolin  50471-44-8  1.5 x10-9 - 1x 10-4
Fluometuron  2164-17-2  1.5 x10-9 - 1x 10-4
Phenothrin  26002-80-2  1.5 x10-8 - 1x 10-3
Chloramphenicol  56-75-7  1.5 x10-8 - 1x 10-3
Quizalofop-ethyl  76578-14-8  1.5 x10-8 - 1x 10-3
Atropine sulfate salt monohydrate  5908-99-6  1.5 x10-8 - 1x 10-3
Pentachlorobenzene  608-93-5  1.5 x10-9 - 1x 10-4
Bisphenol A  80-05-7  1.5 x10-9 - 1x 10-4
Acetaminophen  103-90-2  1.5 x10-8 - 1x 10-3
Tralkoxydim  87820-88-0  1.5 x10-8 - 1x 10-3
Perfluorooctanesulfonic acid  1763-23-1  1.5 x10-8 - 1x 10-3
Trans-Nonachlor  39765-80-5  7.6 x10-9 - 5x 10-4
Alachlor  15972-60-8  1.5 x10-9 - 1x 10-4
Diquat dibromide monohydrate  6385-62-2  1.5 x10-8 - 1x 10-3
Methyl viologen dichloride hydrate  1910-42-5  1.5 x10-8 - 1x 10-3
Zoxamide  156052-68-5  7.6 x10-9 - 5x 10-4
Etridiazole  2593-15-9  1.5 x10-8 - 1x 10-3
Fluazinam  79622-59-6  1.5 x10-9 - 1x 10-4
Copper sulphate  7758-98-7  1.5 x10-8 - 1x 10-3
Terbutryn  886-50-0  7.6 x10-9 - 5x 10-4
Ibuprofen  15687-27-1  1.5 x10-8 - 1x 10-3
Phenytoin  57-41-0  7.6 x10-9 - 5x 10-4
Chloridazon  1698-60-8  1.5 x10-8 - 1x 10-3
Methidathion  950-37-8  1.5 x10-8 - 1x 10-3
Fenarimol  60168-88-9  1.5 x10-9 - 1x 10-4
Oxyfluorfen  42874-03-3  7.6 x10-9 - 5x 10-4
Endosulfan (alpha)  959-98-8  1.5 x10-8 - 1x 10-3
Cycloheximide  66-81-9  7.6 x10-9 - 5x 10-4
Benzo[a]Pyrene  50-32-8  1.5 x10-10 - 1x 10-5
Dazomet  533-74-4  1.5 x10-8 - 1x 10-3
Triclosan  3380-34-5  7.6 x10-9 - 5x 10-4
Nilutamide  63612-50-0  1.5 x10-9 - 1x 10-4
Captafol  2425-06-1  7.6 x10-9 - 5x 10-4
Acetochlor  34256-82-1  1.5 x10-8 - 1x 10-3
Diethylstilbestrol 56-53-1  1.5 x10-9 - 1x 10-4
Flutamide  13311-84-7  1.5 x10-9 - 1x 10-4
Tamoxifen  10540-29-1  7.6 x10-9 - 5x 10-4
Chlorpromazine hydrochloride  69-09-0  7.6 x10-9 - 5x 10-4
Amiodarone hydrochloride  19774-82-4  1.5 x10-9 - 1x 10-4
Cyhalothrin (@Karate)  91465-08-6  1.5 x10-8 - 1x 10-3
METHYLMERCURY(II) CHLORIDE  115-09-3  7.6 x10-9 - 5x 10-4
Permethrin  52645-53-1  1.5 x10-8 - 1x 10-3
Strychnidin-10-one, 2,3-dimethoxy-aldrin  357-57-3  1.5 x10-8 - 1x 10-3
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served (Alessenko et al., 1997; Sánchez et al., 1997). Other 
chemicals, such as acetaminophen, a well-known oxidative 
stress inducer compound, showed an increase of ROS forma-
tion at a lower dose than the concentration at which an effect 
on cell viability is observed (Fig. 4e) (McGill et al., 2011). 
Dibutyl-phthalate was non-toxic at the tested concentration 
in HepaRG cells (Fig. 4F). Figure 5 shows a summary of our 
multiparametric analysis results. the lowest concentration at 
tenone, cycloheximide, acetaminophen, and dibutyl-phthalate. 
In accordance with what is known about the mechanisms of 
liver toxicity, amiodarone hydrochloride (Spaniol et al., 2001; 
Waldhauser et al., 2006) (Fig. 4A), troglitazone (Narayanan 
et al., 2003; Uetrecht, 2010) (Fig. 4B), and rotenone (terzi et 
al., 2004) (Fig. 4C) caused oxidative stress at low concentra-
tion. Chemicals such as cycloheximide (Fig. 4D) induced cell 
death, as previously reported, but no ROS formation was ob-
Compound  CAS #  Tested in vitro concentration range (M)
Aldrin  309-00-2  7.6 x10-9 - 5x 10-4
Acetylsalicylic acid  50-78-2  1.5 x10-8 - 1x 10-3
Dinoseb  88-85-7  1.5 x10-8 - 1x 10-3
Flusilazole  85509-19-9  7.6 x10-9 - 5x 10-4
Cyproconazol  94361-06-5  7.6 x10-9 - 5x 10-4
Cypermethrin  52315-07-8  1.5 x10-8 - 1x 10-3
Cyfluthrin  68359-37-5  1.5 x10-8 - 1x 10-3
Bisphenol A diglycidyl ether  1675-54-3  1.5 x10-8 - 1x 10-3
Pendimethalin  40487-42-1  1.5 x10-8 - 1x 10-3
Pyriproxyfen  95737-68-1  1.5 x10-8 - 1x 10-3
Lactofen  77501-63-4  1.5 x10-8 - 1x 10-3
Sodium dodecyl sulfate  151-21-3  1.5 x10-8 - 1x 10-3
Warfarin  81-81-2  1.5 x10-9 - 1x 10-4
Verapamil hydrochloride  152-11-4  1.5 x10-8 - 1x 10-3
Propiconazole  60207-90-1  7.6 x10-9 - 5x 10-4
2-Acetamidofluorene  53-96-3  7.6 x10-9 - 5x 10-4
Myclobutanil  88671-89-0  7.6 x10-9 - 5x 10-4
Fludioxonil  131341-86-1  7.6 x10-9 - 5x 10-4
Hexaconazol  79983-71-4  7.6 x10-9 - 5x 10-4
Perfluorooctanioic acid  335-67-1  1.5 x10-8 - 1x 10-3
Omeprazole  73590-58-6  1.5 x10-8 - 1x 10-3
Nitrofen  1836-75-5  1.5 x10-8 - 1x 10-3
Troglitazone  97322-87-7  1.5 x10-9 - 1x 10-4
Haloperidol  52-86-8  1.5 x10-9 - 1x 10-4
S-Bioallethrin  28434-00-6  1.5 x10-8 - 1x 10-3
Prallethrin  23031-36-9  1.5 x10-8 - 1x 10-3
Imazalil  35554-44-0  7.6 x10-9 - 5x 10-4
Thiophanate-methyl  23564-05-8  1.5 x10-8 - 1x 10-3
Pentachlorophenol  87-86-5  1.5 x10-9 - 1x 10-4
Cadmium chloride  10108-64-2  1.5 x10-9 - 1x 10-4
Rotenone  83-79-4  1.5 x10-9 - 1x 10-4
Strychnine  57-24-9  1.5 x10-9 - 1x 10-4
Bis(2-ethylhexyl) phthalate  117-81-7  1.5 x10-8 - 1x 10-3
dimethylcarbamoyl chloride  79-44-7  1.5 x10-8 - 1x 10-3
Norflurazon  27314-13-2  1.5 x10-9 - 1x 10-4
4-Nitrotoluene  99-99-0  1.5 x10-8 - 1x 10-3
Simazine  122-34-9  1.5 x10-9 - 1x 10-4
2-Propylpentanoic acid  99-66-1  1.5 x10-9 - 1x 10-4
Dibutyl phthalate  84-74-2  1.5 x10-9 - 1x 10-4
Propyl 4-hydroxybenzoate  94-13-3  1.5 x10-9 - 1x 10-4
Genistein  446-72-0  1.5 x10-9 - 1x 10-4
DL-thyroxin  51-48-9  1.5 x10-9 - 1x 10-4
Potassium Chloride  7447-40-7  1.5 x10-9 - 1x 10-4
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Fig. 2: Steps involved in the 92 selected chemicals screening
Two week-old confluent differentiated HepaRG cells were seeded in 96 well plates and then treated for 72 h with serial dilutions of 
92 chemicals. Treated cells were stained with two fluorescent dyes: Hoechst and DHE fixed with 4% formaldehyde and imaged using 
Cellomics Arrayscan vTi.
Fig. 3: High-content analysis on HepaRG cells
A) Hoechst dye was used to stain the cell nuclei and dihydroethidium (DHE) oxidation was employed to measure production of ROS. In 
the presence of reactive oxygen species, DHE is oxidised to give a fluorescent ethidium product able to intercalate with DNA. 
B) Comparative DHE signal observed using fluorescent imaging after cells are exposed to vehicle control (DMSO) and 100 μM Rotenone 
(positive control for oxidative stress) for 72 h. The control well shows densely populated hepatocyte colonies with low DHE signal while 
rotenone-treated cells are reduced in number and size, and show increased nuclear and red DHE signal (in the composite) intensity. 
10x
Hoechst DHE Composite
DMSO
100 M
Rotenone
Fig. 3B 
Fig. 3 A
Fig. 3 B
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Fig. 4: Effects of HepaRG exposure to chemicals
48 h after seeding, cells were treated with chemicals for 72 h. Results are means of three biological repeats. Intensity of nuclear and ROS 
markers was measured as an average of the overall cell population and PODs were determined (see data analysis methods section). 
Quantification by imaging analysis indicates that at higher concentrations amidarone hydrochloride (A) and troglitazone (B) induce ROS 
but have no effect on cell viability. (C) As expected, rotenone, used as a positive control, has a clear positive result for all four tested 
endpoints. (D) Cycloheximide is an example where toxicity, observed as a decrease in cell count and changes in nuclear morphology, 
does not show a relationship with an increase in ROS. (E) Lower concentrations of acetaminophen increase ROS signal and have an 
effect on cell viability only at higher concentrations. (F) No response was obtained treating HepaRG cells for 72 h with dibutyl phthalate.
Fig. 4 E
Fig. 4 F
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which a POD was calculated for any of the parameters meas-
ured was used to profile the test chemicals. We used a scale of 
colors from yellow to light blue to specify the concentration at 
which there is a response compared to control. this allowed us 
to identify and group together those chemicals with a similar 
response. Chemicals with similar profiles may likely have a 
common hepatotoxicity MoA. We observed that rotenone, cad-
mium chloride, and imazalil affected all 4 tested parameters at 
a dose lower than 20 µM. Also, omeoprazole, perfluoroocta-
noic acid, fludioxonil, lactofen, pyriproxyfen, cypermethrin, 
and cyfluthrin induced generation of ROS, DNA condensation, 
and cell loss, but only at higher doses. Some chemicals, such 
as carbamazepine, kaempferol, 1,2-dichlorobenzene, phthalic 
anhydride, triticonazole, thiabendazole, vinclozolin, acetylsal-
icylic acid, pentachlorobenzene, and bisphenol A formed ROS 
but no cell loss was observed. At 72 h exposure, phenothrin, 
chloramphenicol, quizalofop-ethyl, trans-nonachlor, alachlor, 
diquat dibromide monohydrate, methyl viologen dichloride 
hydrate, zoxamide, etridiazole, fluazinam, copper sulphate, 
terbutryn, ibuprofen, methidathion, fenarimol, oxyfluorfen, 
endosulfan, cycloheximide and benzo-a-pyrene demonstrated 
toxicity not associated with ROS formation. For these chemi-
cals earlier time points need to be analyzed. On the other hand, 
12 chemicals (see gray cells in Fig. 5) were not toxic at the 
tested concentrations. 
4  Discussion
the goal of this work is to design an in vitro testing strategy to 
identify chemicals that are potentially hepatotoxic in humans, 
to associate them with specific MoA categories, and to group 
them accordingly. to begin with, we tested oxidative stress 
in HepaRG treated with various hepatotoxic chemicals which 
provided us with insights towards ROS-mediated toxicity and 
MoA-driven chemical testing. 
the metabolically competent HepaRG cell line is a very at-
tractive alternative model for in vitro hepatotoxicity testing. 
Our cell-based screening of 92 chemicals showed that this cell 
model is a promising alternative to either primary hepatocytes 
or other human tumor hepatic cell lines. Moreover, the HepaRG 
are easy to grow and to cryo-preserve.
In this work we have proven that automated cell imaging and 
HCA are feasible using the human hepatoma cell line HepaRG. 
Furthermore, the HCA offers significant advantages over tradi-
tional HtS assays without compromising throughput. As already 
Fig. 5: Clustering of in vitro multiparametric analysis results 
for 92 test chemicals
Target Activation Bioapplication v.4 from Cellomics Scan software 
was used to obtain data on four parameters: cell count, nuclear 
intensity, nuclear area and ROS intensity. Following analysis, the 
chemicals were characterized to determine the concentration at 
which a positive result is observed for each endpoint. The different 
colours specify the concentration at which there is a response 
compared to control.
Fig. 5
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